PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE

Bibliografske podrobnosti
Main Authors:	I. Serin, B. ORHAN, D. SONMEZ, T. A. CINLI, H. GOZE, H. SERIN, O. YOKUS
Format:	Article
Jezik:	English
Izdano:	Wiley 2022-06-01
Serija:	HemaSphere
Online dostop:	http://journals.lww.com/10.1097/01.HS9.0000850216.89828.d5

Podobne knjige/članki

PB1752: SAMATYA-PREDICTING SCORE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): COMBINING CLINICAL FEATURES WITH FLOW CYTOMETRY
od: Tahir Alper Cinli, et al.
Izdano: (2023-08-01)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
od: Osman Yokus, et al.
Izdano: (2023-08-01)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
od: Lewis Nasr, et al.
Izdano: (2023-08-01)

AngioCRIME in Acute Myeloid Leukemia (AML)
od: Elizabeth Macintyre, et al.
Izdano: (2017-12-01)

PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
od: Marta Pereira, et al.
Izdano: (2023-08-01)

Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
od: Omer Jamy, et al.
Izdano: (2024-10-01)

PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)
od: Giovanna Piras, et al.
Izdano: (2023-08-01)

Acute Myeloid Leukemia (AML): The Role of Intensive Induction Chemotherapy
od: Thomas Büchner, et al.
Izdano: (2004-07-01)

PB2075: HOW EFFECTIVE ARE LEPTIN GENE POLYMORPHISMS AND METHYLATION DURING THE COURSE OF MULTIPLE MYELOMA (MM)?
od: Istemi Serin, et al.
Izdano: (2023-08-01)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
od: Oguz Altunok, et al.
Izdano: (2023-08-01)

Acute Myeloid Leukemia (AML) Detection Using AlexNet Model
od: Maneela Shaheen, et al.
Izdano: (2021-01-01)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
od: F. Ong, et al.
Izdano: (2022-06-01)

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
od: Shakeri S., et al.
Izdano: (2021-11-01)

PB1788: A SCREENING OF DONATED CHEMICAL PROBES TO IDENTIFY NOVEL THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA (AML) IN CHILDHOOD
od: Stephanie Laszig, et al.
Izdano: (2023-08-01)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
od: Osman Yokus, et al.
Izdano: (2023-08-01)

Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML)
od: Anthony Crymes, et al.
Izdano: (2024-01-01)

P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)
od: Giorgia Silvestrini, et al.
Izdano: (2023-08-01)

The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
od: Atousa Haghi, et al.
Izdano: (2022-10-01)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
od: Vahit Can Cavdar, et al.
Izdano: (2023-08-01)

PB1852: COMPARISON OF CLINICAL CHARACTERISTICS OF ADULT CHILEAN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), ACCORDING TO THEIR HEALTH CARE SYSTEM: ANALYSIS WITHIN THE FRAMEWORK OF THE PTHEMA AML REGISTRY
od: Monica Romero, et al.
Izdano: (2023-08-01)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
od: Josephine Brysting, et al.
Izdano: (2023-08-01)

Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
od: Ziyang Cao, et al.
Izdano: (2022-11-01)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
od: K. Sun, et al.
Izdano: (2022-06-01)

P1686: LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY
od: Fabio Efficace, et al.
Izdano: (2023-08-01)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
od: Jule Ussmann, et al.
Izdano: (2023-08-01)

PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
od: Amanda Cashen, et al.
Izdano: (2023-08-01)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
od: Ming Sun, et al.
Izdano: (2023-08-01)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
od: Doehner, H, et al.
Izdano: (2017)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
od: E. M. Mahtat, et al.
Izdano: (2022-06-01)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
od: Osman Yokus, et al.
Izdano: (2023-08-01)

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics
od: Fernandez-Mercado, M, et al.
Izdano: (2012)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
od: Z. Stupakova, et al.
Izdano: (2022-06-01)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
od: Qianxing Mo, et al.
Izdano: (2023-08-01)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
od: Olivera Mitrović Ajtić, et al.
Izdano: (2023-08-01)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
od: N. G. Daver, et al.
Izdano: (2022-06-01)

Immunogenic cell death (ICD) genes predict immunotherapy response and therapeutic targets in acute myeloid leukemia (AML)
od: Shuang Wen, et al.
Izdano: (2024-08-01)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
od: Melike Keskin, et al.
Izdano: (2023-08-01)

AN AML CASE PRESENTING WITH EXTRAMEDULLARY MYELOID SARCOMA
od: Songül Beskisiz Dönen, et al.
Izdano: (2024-12-01)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
od: G. Paterno, et al.
Izdano: (2022-06-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
od: N. Daver, et al.
Izdano: (2022-06-01)